Biologic-drug Combination Product

A drug manufacturer sought Chimera’s advice on clinical development, marketing authorization and labeling strategy for the combined use of its drug with a licensed biologic where the biologic manufacturer was not collaborating on the development of the combined use of the two products. Chimera prepared a strategy document for the drug manufacturer summarizing development, registration and labeling options available to the drug developer the under these circumstances.